Filing Flows › Materials › Pure Bioscience (PURE)
Pure Bioscience (PURE) earnings and revenue breakdown
Latest: Q4 FY26 · 10-K filed Oct 29, 2026 · Pure Bioscience (PURE) Q4 FY26 earnings results →
Q4 FY26 Revenue down 14% year over year to $659K · 93¢ of every $1 of revenue lost · operating margin -76.3%
Pure Bioscience made $659K in Q4 FY26 (-14% Y/Y): Product $659K, Royalty $1K. Operating margin -76.3%, net loss $610K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $659K in Q4 FY26, down 14% year over year and up 30% from the previous quarter. PURE Hard Surface was the largest line at 96% of revenue.
Gross margin was 56.0%, down 5.3 points from Q4 FY25. Operating costs exceeded revenue by $503K, an operating margin of -76.3%. Operating expenses grew 8% against a revenue fall of 14%. The fastest-growing cost line was Research & development (+27%). The quarter ended with a net loss of $610K, narrower than the previous quarter's $624K loss.
Operating cash flow was −$414K. Non-cash charges added back $1K of depreciation and $50K of share-based compensation. Working capital and other items added $145K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 FY26 | 10-K | Oct 29, 2026 | $659K | -14% | -76.3% | −$610K | −$414K |
| Q3 FY26 | 10-Q | Jun 15, 2026 | $506K | +4% | -102.4% | −$624K | −$468K |
| Q2 FY26 | 10-Q | Mar 17, 2026 | $443K | +13% | -154.2% | −$785K | −$606K |
| Q1 FY26 | 10-Q | Dec 15, 2025 | $707K | +27% | -53.6% | −$464K | −$250K |
| Q4 FY25 | 10-K | Oct 29, 2025 | $763K | +62% | -44.0% | −$332K | −$456K |
| Q3 FY25 | 10-Q | Jun 16, 2025 | $489K | +11% | -119.4% | −$580K | −$512K |
| Q2 FY25 | 10-Q | Mar 17, 2025 | $391K | +20% | -185.4% | −$798K | −$544K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Pure Bioscience
We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC. This broad-spectrum, non-toxic antimicrobial agent is available in liquid form and various concentrations, distinguished by its superior efficacy, reduced toxicity, non-causticity, and the inability of bacteria to develop resistance.
In its own words, from its 10-K, filed Oct 29, 2026.
Pure Bioscience against its Miscellaneous Chemical Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -14% against the peers' median +9%. Operating margin: -76.3% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PURE Pure Bioscience | Q4 FY26 | $659K | -14% | -76.3% |
| CBT Cabot | Q4 FY26 | $1.0B | +12% | 12.0% |
| ESI Element Solutions | Q3 2026 | $995M | +52% | 11.4% |
| OEC Orion S.A. | Q3 2026 | $473M | +5% | 4.8% |
| WDFC WD 40 | Q4 FY26 | $177M | +8% | 10.8% |
| FTK Flotek Industries | Q3 2026 | $114M | +104% | 15.7% |
| ARQ Arq | Q3 2026 | $38.2M | +9% | 8.2% |
| FSI Flexible Solutions International | Q2 2026 | $7.6M | -33% | -29.2% |
| ASPI ASP Isotopes | Q2 2026 | $5.1M | +328% | -667.5% |
Source: Pure Bioscience 10-K on SEC EDGAR · CIK 1006028 · Miscellaneous Chemical Products
More on PURE
History
Every quarter: Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results